At 10.4x earnings and just 6.9x forward earnings with a PEG of 0.5, this stock is priced like a no-growth cyclical despite clear signals of earnings acceleration. The valuation is undeniably compressed for a Consumer Defensive name, and the 4.8 Altman Z-Score suggests minimal bankruptcy risk, reinforcing balance sheet stability despite operational noise. A 0.8 Price/Sales ratio adds to the deep value narrative. However, the disconnect between current EPS of 8.5 and next year’s estimate of 1.47 raises serious earnings durability questions. The market is pricing in skepticism, but if forward earnings materialize as expected, this looks materially mispriced on a GARP basis.